Aldurazyme
laronidase
Laronidase
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor or your pharmacist.
This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
If you get any side effects talk to your doctor or pharmacist. This includes any possible side
effects not listed in this leaflet. See section 4.
What Aldurazyme is and what it is used for
What you need to know before you are given Aldurazyme
How Aldurazyme is given
Possible side effects
How to store Aldurazyme
Contents of the pack and other information
Aldurazyme is used to treat patients with MPS I disease (Mucopolysaccharidosis I). It is given to treat the non-neurological manifestations of the disease.
People with MPS I disease have either a low level or no level of an enzyme called α-L-iduronidase, which breaks down specific substances (glycosaminoglycans) in the body. As a result, these substances do not get broken down and processed by the body as they should. They accumulate in many tissues in the body, which causes the symptoms of MPS I.
Aldurazyme is an artificial enzyme called laronidase. This can replace the natural enzyme which is lacking in MPS I disease.
If you are allergic (hypersensitive) to laronidase or any of the other ingredients of this medicine (listed in section 6).
Talk to your doctor before using Aldurazyme. If you are treated with Aldurazyme, you may develop infusion-associated reactions. An infusion-associated reaction is any side effect occurring during the infusion or until the end of the infusion day (see section 4 “Possible Side Effects”). Some of these reactions may be severe. When you experience such a reaction, you should immediately contact your doctor.
If these reactions occur, the Aldurazyme infusion should be stopped immediately and appropriate treatment will be started by your doctor.
These reactions may be particularly severe if you have a pre-existing MPS I-related upper airway obstruction.
You may be given additional medication such as antihistamines and paracetamol to help prevent
allergic-type reactions.
Inform your doctor if you are using medicines containing chloroquine or procaine, due to a possible risk of decreasing the action of Aldurazyme.
Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
There is not enough experience of the use of Aldurazyme in pregnant women. You should not be given Aldurazyme during pregnancy unless clearly necessary.
It is not known whether Aldurazyme appears in breast milk. It is recommended to stop breast-feeding during treatment with Aldurazyme.
No information is available on the effects of Aldurazyme on fertility.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
The effects on the ability to drive and to use machines have not been studied.
This medicine contains 30 mg sodium (main component of cooking/table salt) per vial. This is equivalent to 1.5% of the recommended maximum daily dietary intake of sodium for an adult.
Instruction for use - dilution and administration
The concentrate for solution for infusion has to be diluted before administration and is for intravenous use (see information for health care professionals).
Administration of Aldurazyme should be carried out in an appropriate clinical setting where
resuscitation equipment to manage medical emergencies would be readily available.
Dosage
The recommended dosage regimen of Aldurazyme is 100 U/kg body weight given once every week as an intravenous infusion. The initial infusion rate of 2 U/kg/h may be gradually increased every fifteen minutes, if tolerated, to a maximum of 43 U/kg/h. The total volume of the administration should be delivered in approximately 3-4 hours.
Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.
If you have missed an Aldurazyme infusion, please contact your doctor.
No case of overdose of Aldurazyme has been reported.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Side effects were mainly seen while patients were being given the medicine or shortly after (infusion- associated reactions). If you experience any reaction like this, you should contact your doctor immediately. The number of these reactions decreased the longer that patients were on Aldurazyme. The majority of these reactions were mild or moderate in intensity. However, severe systemic allergic reaction (anaphylactic reaction) has been observed in patients during or up to 3 hours after Aldurazyme infusions. Some of the symptoms of such a severe allergic reaction were life-threatening and included extreme difficulty breathing, swelling of the throat, low blood pressure, and low oxygen level in the body. A few patients who had a prior history of severe MPS I related upper airway and pulmonary involvement, experienced severe reactions including bronchospasm (airway constriction), respiratory arrest, and swelling of the face. The frequency of bronchospasm and respiratory arrest is unknown. The frequency of severe allergic reaction (anaphylactic reaction) and swelling of the face is considered common and may affect up to 1 in 10 people.
Very common symptoms (may affect more than 1 in 10 people) which were not serious include headache, nausea, abdominal pain, rash, joint disease, joint pain, back pain, pain in arms or legs, flushing, fever, chills, increased heart rate, increased blood pressure, and reaction at the infusion site.
Other side effects include the following:
increased body temperature
tingling
dizziness
cough
difficulty in breathing
vomiting
diarrhoea
swelling of the neck
hives
itching
hair loss
cold sweat, heavy sweating
muscle pain
paleness
cold hands or feet
feeling hot, feeling cold
fatigue
influenza like illness
restlessness
bluish color of the skin (due to lower levels of oxygen in the blood)
fast breathing
redness of the skin
leakage of the drug into the surrounding tissue at the site of injection, which may cause swelling or redness
swelling of arms and/or legs
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
You should not be given this medicine after the expiry date which is stated on the label after the letters EXP. The expiry date refers to the last day of that month.
Unopened vials:
Store in a refrigerator (2°C – 8°C).
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The active substance is laronidase. One ml of the solution in the vial contains 100 U of laronidase. Each vial of 5 ml contains 500 U of laronidase.
The other ingredients are sodium chloride, sodium phosphate monobasic monohydrate, sodium
phosphate dibasic heptahydrate, polysorbate 80, water for injections.
Aldurazyme is supplied as a concentrate for solution for infusion. It is a solution that is clear to slightly opalescent, and colourless to pale yellow.
Pack size: 1, 10 and 25 vials per carton. Not all pack sizes may be marketed.
Marketing Authorisation Holder
Genzyme Europe B.V., Paasheuvelweg 25, 1105 BP Amsterdam, The Netherlands.
Manufacturer
Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Tél/Tel: + 32 2 710 54 00
Swixx Biopharma EOOD
Тел.: +359 (0)2 4942 480
Sanofi S.r.l.
Tel: +39 02 39394275
Genzyme Europe B.V. Tel: +31 20 245 4000
Sanofi A/S
Tlf: +45 45 16 70 00
sanofi-aventis Norge AS Tlf: + 47 67 10 71 00
Sanofi-Aventis Deutschland GmbH Tel.: 0800 04 36 996
Tel. aus dem Ausland: +49 69 305 7013
sanofi-aventis GmbH Tel: + 43 1 80 185 – 0
Swixx Biopharma OÜ Tel. +372 640 10 30
sanofi-aventis Sp. z o.o. Tel: +48 22 280 00 00
sanofi-aventis AEBE
Τηλ: +30 210 900 1600
Sanofi – Produtos Farmacêuticos, Lda. Tel: +351 21 35 89 400
sanofi-aventis, S.A. Tel: +34 93 485 94 00
Sanofi Romania SRL Tel: +40 (0) 21 317 31 36
sanofi-aventis France Tél: 0 800 222 555
Appel depuis l’étranger: +33 1 57 63 23 23
Swixx Biopharma d.o.o. Tel: +386 1 235 51 00
Swixx Biopharma d.o.o Tel: +385 1 2078 500
sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +353 (0) 1 403 56 00
Sanofi Oy
Puh/Tel: + 358 201 200 300
Vistor hf.
Sími: +354 535 7000
Sanofi AB
Tel: +46 (0)8 634 50 00
Sanofi S.r.l. Tel: 800536389
C.A. Papaellinas Ltd.
Τηλ: +357 22 741741
Swixx Biopharma SIA Tel: +371 6 616 47 50
Swixx Biopharma UAB Tel. +370 5 236 91 40
There are also links to other websites about rare diseases and treatments.
This leaflet is available in all EU/EEA languages on the European Medicines Agency website.
--------------------------------------------------------------------------------------------------------------------------
The following information is intended for healthcare professionals only:
Each vial of Aldurazyme is intended for single use only. The concentrate for solution for infusion has to be diluted with sodium chloride 9 mg/ml (0.9%) solution for infusion using aseptic technique. It is recommended that the diluted Aldurazyme solution be administered to patients using an infusion set equipped with an 0.2 µm in-line filter.
From a microbiological safety point of view, the product should be used immediately. If not used immediately, in-use storage should not be longer than 24 hours at 2°C - 8°C provided that dilution has taken place under controlled and validated aseptic conditions.
Aldurazyme should not be mixed with other medicinal products in the same infusion.
Determine the number of vials to be diluted based on the individual patient's weight. Remove the required vials from the refrigerator approximately 20 minutes in advance in order to allow them to reach room temperature (below 30˚C).
Before dilution, visually inspect each vial for particulate matter and discoloration. The clear to slightly opalescent and colourless to pale yellow solution should be free of visible particles. Do
not use vials exhibiting particles or discoloration.
Determine the total volume of infusion based on the individual patient's weight, either 100 ml (if bodyweight is less or equal than 20 kg) or 250 ml (if bodyweight is more than 20 kg) of 0.9%
sodium chloride intravenous solution.
Withdraw and discard a volume of sodium chloride 9 mg/ml (0.9%) solution for infusion from the infusion bag equal to the total volume of Aldurazyme to be added.
Withdraw the required volume from the Aldurazyme vials and combine the withdrawn volumes.
Add the combined volumes of Aldurazyme to the sodium chloride 9 mg/ml (0.9%) solution for infusion.
Mix the solution for infusion gently.
Prior to use visually inspect the solution for particulate matter. Only clear and colourless solutions without visible particles should be used.
Any unused product or waste material should be disposed of in accordance with local requirements.